FDA Sticks Breakthrough Tag on GlaxoSmithKline's Blood Cancer Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate. Source: BioSpace You Might Also Like AstraZeneca PLC Loses $10 Billion in Value as Long-Awaited MYSTIC Trial Disappoints July 26, 2017 Polyphor Announces Successful End Of Phase II Meeting With FDA For Murepavadin In Nosocomial Pneumonia May 18, 2017 All Signs Have Gilead Gearing Up for a Much-Needed Acquisition February 12, 2017
Polyphor Announces Successful End Of Phase II Meeting With FDA For Murepavadin In Nosocomial Pneumonia May 18, 2017
